CREATINE-LIGAND COMPOUNDS AND METHODS OF USE THEREOF

• US 20110008306A1
• Filed: 02/02/2010
• Published: 01/13/2011
• Est. Priority Date: 05/11/2006
• Status: Abandoned Application

• Current Assignee: Library Pharma, Inc.
• Original Assignee: Library Pharma, Inc.
• Inventors: Nivaggioli, Belinda Tsao
• Application Number:
  US12/698,527
• Publication Number:
  US 20110008306A1
• Time in Patent Office: Days
• US Class Current: 424/94.1
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/185 Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids hydroxamic acids A61K31/16; peroxy acids A61K31/327
• CPC Class Codes: A61K 31/375 Ascorbic acid, i.e. vitamin C; Salts thereof
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61K 47/542 Carboxylic acids, e.g. a fatty acid or an amino acid
• CPC Class Codes: A61K 47/551 one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
• CPC Class Codes: A61P 17/00 Drugs for dermatological disorders
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 25/16 Anti-Parkinson drugs

Abstract

The present invention provides methods of treating creatine responsive states, such as a neurological disorder (i.e., Huntington'"'"'s disease, Parkinson'"'"'s disease, amyotrophic lateral sclerosis and creatine transporter defect) or a skin disorder, by administering a creatine-ligand compound, alone or in combination with an anti-inflammatory compound, to a subject.

Claims

1. A composition comprising creatine bound to a ligand to form a creatine-ligand compound, wherein the creatine-ligand compound has a ratio of between about 1:

1 creatine to ligand and about 10;

1 creatine to ligand.

2-4. -4. (canceled)

5. The composition of claim 1, wherein the ligand comprises an amino acid or a water-soluble vitamin.

6-8. -8. (canceled)

9. The composition of claim 1, wherein the ligand is selected from the group consisting of cinnamate, lactate, glycolate, malate, mandelate, ascorbate, phytate, citrate, hydroxycitrate, aleurate, salicylate and hyaluronate.

10-20. -20. (canceled)

21. A method of treating a creatine responsive state in a subject comprising administering to said subject a composition comprising an effective amount of a creatine-ligand compound such that the creatine responsive state in said subject is treated.

22. (canceled)

23. (canceled)

24. The composition of claim 21, wherein said creatine responsive state is a neurological disorder or a skin disorder.

25-51. -51. (canceled)

52. The method of claim 21, further comprising administering to said subject an effective amount of an anti-inflammatory compound.

53. The method of claim 52, wherein said neurological disorder is Huntington'"'"'s disease, Parkinson'"'"'s disease, creatine transporter defect or amyotrophic lateral sclerosis.

54-60. -60. (canceled)

61. The method of claim 52, wherein the anti-inflammatory compound is a member of the tetracycline family or a cyclooxygenase-2 (COX-2) selective inhibitor.

62-73. -73. (canceled)

74. A pharmaceutical composition comprising an effective amount of a creatine-ligand compound and an acceptable carrier, wherein said effective amount is effective for the treatment of a creatine responsive state.

75. The pharmaceutical composition of claim 74, further comprising an effective amount an anti-inflammatory compound.

76-96. -96. (canceled)

97. The method of claim 21, wherein said composition further comprises co-enzyme Q₁₀, ethyl-eicosapentanopic acid, a glutamate antagonist or phenylbutyrate.

98. (canceled)